Skip to content

Erythropoietin and Magnesium Sulphate in Hypoxic Ischaemic Encelpalopathy

The Role of Erythropoietin and Magnesium Sulphate in Hypoxic Ischaemic Encephalopathy: Hope for the Perinatally Asphyxiated

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR201812814507775
Enrollment
120
Registered
2018-12-12
Start date
2020-02-17
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal Diseases Pregnancy and Childbirth

Interventions

Erythropoietin
Magnesium Sulfate
Normal Saline

Sponsors

Ezenwa Beatrice
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All term newborns (= 37weeks gestation) diagnosed of perinatal asphyxia at admission and who are <72 hours of age. Evidence of Perinatal depression based on delayed cry at birth and at least one criteria on Sarnat and Sarnat HIE grading

Exclusion criteria

Exclusion criteria: Severe congenital anomalies Preterm babies Infants >72 hours of age at time of presentation /consent Those in which consent could not be obtained Evidence of sepsis (confirmed according to unit protocol)

Design outcomes

Primary

MeasureTime frame
Survival at discharge or Death within the first two years of life and Neurodevelopmental impairment at 6, 12, 18 and 24 months of age

Secondary

MeasureTime frame
Association between the levels of NRBC and NRBC/100WBC with neonatal outcome Safety of the medications based on the presence or absence of any adverse event

Countries

Nigeria

Contacts

Public ContactBeatrice Ezenwa

Consultant Pediatrician

beatriceezenwa@yahoo.com+2348051403189

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026